Skip to content
AnalystLens

Price T Rowe Group 8-K Report, Executive Changes (Feb 20, 2024)

Reports
Leadership Changes
Filing Date
Filed February 20, 2024
Period End
February 16, 2024
Security
TROW
In the record · 2016–202610-K1110-Q338-K83

TROW filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 83 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Apr ’22Apr ’22
  2. Leadership change8-K · May ’26May ’26

Summary

Summary of the 8-K filed February 20, 2024. Cited figures are marked; the original filing is the authoritative source.

T.

Rowe Price Group, Inc. (NASDAQ-GS: TROW) filed an 8-K on February 20, 2024 to disclose board leadership changes. William J. Stromberg, the non-executive Chair of the Board, and Dr. Freeman A.

Hrabowski, III, informed the Board on February 16, 2024 that they will retire at the Company's 2024 Annual Meeting of Stockholders, currently scheduled for May 7, 2024. Both will continue serving on the Board until that meeting. The filing states that neither retirement resulted from any disagreement with the Company or its management.

Dr. Hrabowski chairs the Nominating and Corporate Governance Committee. Following Mr. Stromberg's retirement, Robert W. Sharps will become Chair of the Board while continuing as Chief Executive Officer and President.

The Board stated that combining the Chair and CEO roles was the right choice given Mr. Sharps's strong leadership through challenging times. Lead Independent Director Alan Wilson praised Mr. Stromberg's contributions, including the launch of T. Rowe Price Investment Management and the firm's global expansion, and credited Dr. Hrabowski with leading the Board's review of corporate social responsibility and ESG efforts.

For investors, the filing is primarily a governance update: it consolidates the Chair and CEO roles under one executive, which is a notable structural change, while the filing reports no financial results. The press release accompanying the filing describes T. Rowe Price as managing USD $1.45 trilliona in assets under management as of January 31, 2024.

Key Highlights

  1. William J. Stromberg, non-executive Chair of the Board, and Dr. Freeman A. Hrabowski, III, will retire at the 2024 Annual Meeting of Stockholders, scheduled for May 7, 2024.
  2. Both directors will continue serving on the Board until the annual meeting, and their retirements were not the result of any disagreement with the Company or its management.
  3. Robert W. Sharps will become Chair of the Board following Mr. Stromberg's retirement, while continuing as Chief Executive Officer and President, combining the Chair and CEO roles.
  4. The Board stated that combining the Chair and CEO roles was the right choice given Mr. Sharps's strong leadership through challenging times.
  5. Dr. Hrabowski served as chair of the Nominating and Corporate Governance Committee, where he led the Board's review of corporate social responsibility and ESG efforts.
  6. Lead Independent Director Alan Wilson credited Mr. Stromberg with launching T. Rowe Price Investment Management (TRPIM) and leading the firm's significant global expansion.
  7. The accompanying press release states T. Rowe Price manages USD $1.45 trillion in assets under management as of January 31, 2024.

Frequently Asked Questions

  1. Why are Mr. Stromberg and Dr. Hrabowski retiring from the Board?

    The filing states that neither retirement was the result of any disagreement with the Company or its management. Both informed the Board on February 16, 2024, and will remain on the Board until the 2024 Annual Meeting of Stockholders on May 7, 2024.

  2. Who will lead the Board after Mr. Stromberg retires?

    Robert W. Sharps, who currently serves as Chief Executive Officer and President, will become Chair of the Board. The Board stated that combining the Chair and CEO roles was the right choice given his strong leadership through challenging times.

  3. Will Mr. Sharps still serve as CEO after becoming Chair?

    Yes. The filing states that Mr. Sharps will continue as Chief Executive Officer and President of the Company in addition to serving as Chair of the Board.

  4. Who will chair the Nominating and Corporate Governance Committee after Dr. Hrabowski's departure?

    The filing does not name a successor. It states only that Dr. Hrabowski is chair of the Nominating and Corporate Governance Committee, which he led in reviewing the firm's corporate social responsibility and ESG efforts.